{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:16:10Z","timestamp":1790766970483,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T00:00:00Z","timestamp":1341964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T00:00:00Z","timestamp":1341964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/leu.2012.188","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T06:39:15Z","timestamp":1341988755000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities"],"prefix":"10.1038","volume":"27","author":[{"given":"M","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Cowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"key":"BFleu2012188_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/PAS.0b013e31814b226e","volume":"32","author":"F Vega","year":"2008","unstructured":"Vega F, Medeiros LJ, Davuluri R, Cromwell CC, Alkan S, Abruzzo LV . t(8;13)-Positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol 2008; 32: 14\u201320.","journal-title":"Am J Surg Pathol"},{"key":"BFleu2012188_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937\u2013951.","journal-title":"Blood"},{"key":"BFleu2012188_CR3","doi-asserted-by":"publisher","first-page":"16198","DOI":"10.1074\/jbc.M300018200","volume":"278","author":"H Baumann","year":"2003","unstructured":"Baumann H, Kunapuli P, Tracy E, Cowell JK . The oncogenic fusion protein-tyrosine kinase ZNF198\/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors. J Biol Chem 2003; 278: 16198\u201316208.","journal-title":"J Biol Chem"},{"key":"BFleu2012188_CR4","doi-asserted-by":"publisher","first-page":"14479","DOI":"10.1073\/pnas.0404438101","volume":"101","author":"J Chen","year":"2004","unstructured":"Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 14479\u201314484.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2012188_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2006-12-065615","volume":"110","author":"S Dong","year":"2007","unstructured":"Dong S, Kang S, Gu TL, Kardar S, Fu H, Lonial S et al. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood 2007; 110: 360\u2013369.","journal-title":"Blood"},{"key":"BFleu2012188_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1535-6108(04)00053-4","volume":"5","author":"S Roumiantsev","year":"2004","unstructured":"Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC et al. Distinct stem cell myeloproliferative\/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004; 5: 287\u2013298.","journal-title":"Cancer Cell"},{"key":"BFleu2012188_CR7","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1158\/0008-5472.CAN-11-1109","volume":"71","author":"M Ren","year":"2011","unstructured":"Ren M, Qin H, Ren R, Tidwell J, Cowell JK . Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. Cancer Res 2011; 71: 7312\u20137322.","journal-title":"Cancer Res"},{"key":"BFleu2012188_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.leukres.2011.05.037","volume":"35","author":"A Holroyd","year":"2011","unstructured":"Holroyd A, Cross NC, Macdonald DH . The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation. Leuk Res 2011; 35: 1279\u20131285.","journal-title":"Leuk Res"},{"key":"BFleu2012188_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1182\/blood-2009-03-212704","volume":"114","author":"M Ren","year":"2009","unstructured":"Ren M, Li X, Cowell JK . Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. Blood 2009; 114: 1576\u20131584.","journal-title":"Blood"},{"key":"BFleu2012188_CR10","doi-asserted-by":"publisher","first-page":"6837","DOI":"10.1182\/blood-2010-07-295725","volume":"117","author":"M Ren","year":"2011","unstructured":"Ren M, Cowell JK . Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. Blood 2011; 117: 6837\u20136847.","journal-title":"Blood"},{"key":"BFleu2012188_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.leukres.2006.04.015","volume":"31","author":"WS Wong","year":"2007","unstructured":"Wong WS, Cheng KC, Lau KM, Chan NP, Shing MM, Cheng SH et al. Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases. Leuk Res 2007; 31: 235\u2013238.","journal-title":"Leuk Res"},{"key":"BFleu2012188_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/00000478-199203000-00003","volume":"16","author":"LV Abruzzo","year":"1992","unstructured":"Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Duca V, Medeiros LJ . T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 1992; 16: 236\u2013245.","journal-title":"Am J Surg Pathol"},{"key":"BFleu2012188_CR13","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.V85.7.1881.bloodjournal8571881","volume":"85","author":"RC Inhorn","year":"1995","unstructured":"Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia\/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995; 85: 1881\u20131887.","journal-title":"Blood"},{"key":"BFleu2012188_CR14","first-page":"1628","volume":"9","author":"D Macdonald","year":"1995","unstructured":"Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC . A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 1995; 9: 1628\u20131630.","journal-title":"Leukemia"},{"key":"BFleu2012188_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","volume":"41","author":"CC Jackson","year":"2010","unstructured":"Jackson CC, Medeiros LJ, Miranda RN . 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; 41: 461\u2013476.","journal-title":"Hum Pathol"},{"key":"BFleu2012188_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116\u2013129.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2012188_CR17","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1182\/blood-2007-02-074286","volume":"110","author":"A Chase","year":"2007","unstructured":"Chase A, Grand FH, Cross NC . Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007; 110: 3729\u20133734.","journal-title":"Blood"},{"key":"BFleu2012188_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2010.036558","volume":"96","author":"B Wasag","year":"2011","unstructured":"Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P . The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia\/lymphoma and t(7;8)(q22;p11). Haematologica 2011; 96: 922\u2013926.","journal-title":"Haematologica"},{"key":"BFleu2012188_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2032Hare","year":"2009","unstructured":"O\u2032Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401\u2013412.","journal-title":"Cancer Cell"},{"key":"BFleu2012188_CR20","unstructured":"Darzynkiewicz Z, Juan G . Analysis of DNA content and BrdU incorporation. Curr Protoc Cytom 2001; Chapter 7: Unit 7.7."},{"key":"BFleu2012188_CR21","doi-asserted-by":"publisher","first-page":"e38265","DOI":"10.1371\/journal.pone.0038265","volume":"7","author":"M Ren","year":"2012","unstructured":"Ren M, Tidwell JA, Sharma S, Cowell JK . Acute progression of BCR-FGFR1 induced murine B-lympho\/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage. PLoS One 2012; 7: e38265.","journal-title":"PLoS One"},{"key":"BFleu2012188_CR22","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1128\/MCB.11.10.5068","volume":"11","author":"M Mohammadi","year":"1991","unstructured":"Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol 1991; 11: 5068\u20135078.","journal-title":"Mol Cell Biol"},{"key":"BFleu2012188_CR23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.V68.5.1101.1101","volume":"68","author":"AJ Furley","year":"1986","unstructured":"Furley AJ, Reeves BR, Mizutani S, Altass LJ, Watt SM, Jacob MC et al. Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines. Blood 1986; 68: 1101\u20131107.","journal-title":"Blood"},{"key":"BFleu2012188_CR24","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.leukres.2006.03.020","volume":"30","author":"S Choi","year":"2006","unstructured":"Choi S, Choi HH, Choi JH, Yoon BH, You HJ, Hyun JW et al. Inhibitory effect of 8-oxo-7,8-dihydro-2\u2032-deoxyguanosine on the growth of KG-1 myelosarcoma in Balb\/c nude mice. Leuk Res 2006; 30: 1425\u20131436.","journal-title":"Leuk Res"},{"key":"BFleu2012188_CR25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1182\/blood.V63.5.1015.1015","volume":"63","author":"EA Machado","year":"1984","unstructured":"Machado EA, Gerard DA, Lozzio CB, Lozzio BB, Mitchell JR, Golde DW . Proliferation and differentiation of human myeloid leukemic cells in immunodeficient mice: electron microscopy and cytochemistry. Blood 1984; 63: 1015\u20131022.","journal-title":"Blood"},{"key":"BFleu2012188_CR26","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.4049\/jimmunol.178.11.7432","volume":"178","author":"N Suciu-Foca","year":"2007","unstructured":"Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 2007; 178: 7432\u20137441.","journal-title":"J Immunol"},{"key":"BFleu2012188_CR27","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","volume":"10","author":"JM Gozgit","year":"2011","unstructured":"Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011; 10: 1028\u20131035.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2012188_CR28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI et al. Ponatinib (AP24534), a multi-targeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012; 11: 690\u2013699.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2012188_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275\u2013284.","journal-title":"Nat Rev Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012188","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:33:45Z","timestamp":1648740825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["BFleu2012188"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.188","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,11]]},"assertion":[{"value":"18 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}